Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results

David F. Archer, Jeffrey Jensen, Julia V. Johnson, Hannah Borisute, Gary S. Grubb, Ginger D. Constantine

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

Objective: This study was conducted to evaluate the safety and efficacy of a continuous daily regimen of levonorgestrel (LNG) 90 μg/ethinyl estradiol (EE) 20 μg (continuous LNG/EE). Methods: Healthy women aged 18-49 years with regular menstrual cycles for 3 months enrolled in this single-treatment open-label study and took one pill of LNG 90 μg/EE 20 μg daily for 12 months. Results: For the 2134 subjects enrolled, the Pearl Index method failure was 1.26, and user failure was 0.34. While on Pill Pack 13, 58.7% of subjects reported amenorrhea and 79.0% reported absence of bleeding. Overall, the number of bleeding and spotting days per pill pack declined progressively. Adverse events and discontinuations were comparable to those reported for cyclic oral contraceptive (OC) regimens, except for higher rates in those related to uterine bleeding. Conclusions: Continuous LNG/EE demonstrated a good safety profile and efficacy similar to cyclic OCs. The regimen continuously inhibited menses, increased the incidence of amenorrhea over time and, except for a subset of women, decreased the number of bleeding and spotting days.

Original languageEnglish (US)
Pages (from-to)439-445
Number of pages7
JournalContraception
Volume74
Issue number6
DOIs
StatePublished - Dec 2006

Fingerprint

Levonorgestrel
Metrorrhagia
Ethinyl Estradiol
Amenorrhea
Hemorrhage
Safety
Menstruation
Uterine Hemorrhage
Menstrual Cycle
Oral Contraceptives
Incidence
levonorgestrel drug combination ethinyl estradiol
Therapeutics

Keywords

  • Amenorrhea
  • Continuous oral contraceptive
  • Levonorgestrel/ethinyl estradiol
  • Menses inhibition

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol : phase 3 study results. / Archer, David F.; Jensen, Jeffrey; Johnson, Julia V.; Borisute, Hannah; Grubb, Gary S.; Constantine, Ginger D.

In: Contraception, Vol. 74, No. 6, 12.2006, p. 439-445.

Research output: Contribution to journalArticle

Archer, David F. ; Jensen, Jeffrey ; Johnson, Julia V. ; Borisute, Hannah ; Grubb, Gary S. ; Constantine, Ginger D. / Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol : phase 3 study results. In: Contraception. 2006 ; Vol. 74, No. 6. pp. 439-445.
@article{2808e55260784870aae477ce3da8410a,
title = "Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results",
abstract = "Objective: This study was conducted to evaluate the safety and efficacy of a continuous daily regimen of levonorgestrel (LNG) 90 μg/ethinyl estradiol (EE) 20 μg (continuous LNG/EE). Methods: Healthy women aged 18-49 years with regular menstrual cycles for 3 months enrolled in this single-treatment open-label study and took one pill of LNG 90 μg/EE 20 μg daily for 12 months. Results: For the 2134 subjects enrolled, the Pearl Index method failure was 1.26, and user failure was 0.34. While on Pill Pack 13, 58.7{\%} of subjects reported amenorrhea and 79.0{\%} reported absence of bleeding. Overall, the number of bleeding and spotting days per pill pack declined progressively. Adverse events and discontinuations were comparable to those reported for cyclic oral contraceptive (OC) regimens, except for higher rates in those related to uterine bleeding. Conclusions: Continuous LNG/EE demonstrated a good safety profile and efficacy similar to cyclic OCs. The regimen continuously inhibited menses, increased the incidence of amenorrhea over time and, except for a subset of women, decreased the number of bleeding and spotting days.",
keywords = "Amenorrhea, Continuous oral contraceptive, Levonorgestrel/ethinyl estradiol, Menses inhibition",
author = "Archer, {David F.} and Jeffrey Jensen and Johnson, {Julia V.} and Hannah Borisute and Grubb, {Gary S.} and Constantine, {Ginger D.}",
year = "2006",
month = "12",
doi = "10.1016/j.contraception.2006.07.005",
language = "English (US)",
volume = "74",
pages = "439--445",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol

T2 - phase 3 study results

AU - Archer, David F.

AU - Jensen, Jeffrey

AU - Johnson, Julia V.

AU - Borisute, Hannah

AU - Grubb, Gary S.

AU - Constantine, Ginger D.

PY - 2006/12

Y1 - 2006/12

N2 - Objective: This study was conducted to evaluate the safety and efficacy of a continuous daily regimen of levonorgestrel (LNG) 90 μg/ethinyl estradiol (EE) 20 μg (continuous LNG/EE). Methods: Healthy women aged 18-49 years with regular menstrual cycles for 3 months enrolled in this single-treatment open-label study and took one pill of LNG 90 μg/EE 20 μg daily for 12 months. Results: For the 2134 subjects enrolled, the Pearl Index method failure was 1.26, and user failure was 0.34. While on Pill Pack 13, 58.7% of subjects reported amenorrhea and 79.0% reported absence of bleeding. Overall, the number of bleeding and spotting days per pill pack declined progressively. Adverse events and discontinuations were comparable to those reported for cyclic oral contraceptive (OC) regimens, except for higher rates in those related to uterine bleeding. Conclusions: Continuous LNG/EE demonstrated a good safety profile and efficacy similar to cyclic OCs. The regimen continuously inhibited menses, increased the incidence of amenorrhea over time and, except for a subset of women, decreased the number of bleeding and spotting days.

AB - Objective: This study was conducted to evaluate the safety and efficacy of a continuous daily regimen of levonorgestrel (LNG) 90 μg/ethinyl estradiol (EE) 20 μg (continuous LNG/EE). Methods: Healthy women aged 18-49 years with regular menstrual cycles for 3 months enrolled in this single-treatment open-label study and took one pill of LNG 90 μg/EE 20 μg daily for 12 months. Results: For the 2134 subjects enrolled, the Pearl Index method failure was 1.26, and user failure was 0.34. While on Pill Pack 13, 58.7% of subjects reported amenorrhea and 79.0% reported absence of bleeding. Overall, the number of bleeding and spotting days per pill pack declined progressively. Adverse events and discontinuations were comparable to those reported for cyclic oral contraceptive (OC) regimens, except for higher rates in those related to uterine bleeding. Conclusions: Continuous LNG/EE demonstrated a good safety profile and efficacy similar to cyclic OCs. The regimen continuously inhibited menses, increased the incidence of amenorrhea over time and, except for a subset of women, decreased the number of bleeding and spotting days.

KW - Amenorrhea

KW - Continuous oral contraceptive

KW - Levonorgestrel/ethinyl estradiol

KW - Menses inhibition

UR - http://www.scopus.com/inward/record.url?scp=33845917050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845917050&partnerID=8YFLogxK

U2 - 10.1016/j.contraception.2006.07.005

DO - 10.1016/j.contraception.2006.07.005

M3 - Article

C2 - 17157099

AN - SCOPUS:33845917050

VL - 74

SP - 439

EP - 445

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 6

ER -